Clover Key Bioscience Inc. (CKB ) was founded by several industry leaders with the aim to find sidelined innovation with significant clinical and business potential. We identified and in-licensed BC1464, a small molecule inhibitor of ubiquitin E3 ligase receptor, a component of FBXO7. This inhibition leads to an increase of PINK1 and improves mitochondrial quality control with potential to impact the treatment outcomes of Parkinson's disease, acute respiratory distress syndrome (ARDS), heart failure, and other neurodegenerative and inflammatory diseases related to aging. We are actively searching for seed funding from institutional and private investors, and potential strategic partners.